Russell Investments Group
ENTA icon

Russell Investments Group’s Enanta Pharmaceuticals ENTA Stock Holding History

Russell Investments Group’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$915K Buy
72,850
+61,367
+534% +$823K ﹤0.01% 2265
2025
Q4 		$182K Sell
11,483
-4,960
-30% -$63K ﹤0.01% 2874
2025
Q3 		$197K Buy
16,443
+1,940
+13% +$15.5K ﹤0.01% 2821
2025
Q2 		$110K Sell
14,503
-902
-6% -$5.43K ﹤0.01% 2799
2025
Q1 		$85K Buy
15,405
+989
+7% +$6.11K ﹤0.01% 2791
2024
Q4 		$82.9K Sell
14,416
-3,104
-18% -$29.8K ﹤0.01% 2725
2024
Q3 		$182K Sell
17,520
-1,369
-7% -$17.9K ﹤0.01% 2538
2024
Q2 		$245K Sell
18,889
-324
-2% -$4.37K ﹤0.01% 2427
2024
Q1 		$335K Sell
19,213
-4,788
-20% -$63.4K ﹤0.01% 2328
2023
Q4 		$226K Sell
24,001
-117
-0.5% -$1.09K ﹤0.01% 2407
2023
Q3 		$269K Sell
24,118
-214
-0.9% -$3.45K ﹤0.01% 2424
2023
Q2 		$521K Buy
24,332
+207
+0.9% +$6.1K ﹤0.01% 2210
2023
Q1 		$976K Sell
24,125
-458
-2% -$21.9K ﹤0.01% 1977
2022
Q4 		$1.14M Buy
24,583
+3,259
+15% +$149K ﹤0.01% 1895
2022
Q3 		$1.1M Buy
21,324
+603
+3% +$35.2K ﹤0.01% 1885
2022
Q2 		$978K Buy
20,721
+5,872
+40% +$319K ﹤0.01% 1971
2022
Q1 		$1.05M Sell
14,849
-5,816
-28% -$378K ﹤0.01% 1932
2021
Q4 		$1.54M Sell
20,665
-11,528
-36% -$905K ﹤0.01% 1929
2021
Q3 		$1.83M Sell
32,193
-1,495
-4% -$73.9K ﹤0.01% 1881
2021
Q2 		$1.48M Sell
33,688
-52,689
-61% -$2.58M ﹤0.01% 2102
2021
Q1 		$4.23M Sell
86,377
-17,115
-17% -$854K 0.01% 1449
2020
Q4 		$4.34M Sell
103,492
-4,202
-4% -$185K 0.01% 1309
2020
Q3 		$4.91M Sell
107,694
-28,972
-21% -$1.4M 0.01% 1139
2020
Q2 		$6.82M Buy
136,666
+3,840
+3% +$199K 0.02% 922
2020
Q1 		$6.81M Buy
132,826
+27,954
+27% +$1.49M 0.02% 810
2019
Q4 		$6.47M Buy
104,872
+7,544
+8% +$468K 0.01% 1069
2019
Q3 		$5.86M Buy
97,328
+7,823
+9% +$581K 0.01% 1113
2019
Q2 		$7.51M Buy
89,505
+1,890
+2% +$170K 0.01% 1024
2019
Q1 		$8.35M Sell
87,615
-1,332
-1% -$119K 0.02% 984
2018
Q4 		$6.25M Sell
88,947
-2,757
-3% -$211K 0.01% 1030
2018
Q3 		$8.06M Buy
91,704
+8,152
+10% +$817K 0.02% 1043
2018
Q2 		$9.5M Buy
83,552
+39,908
+91% +$3.98M 0.02% 943
2018
Q1 		$3.53M Buy
43,644
+23,305
+115% +$1.79M 0.01% 1539
2017
Q4 		$1.21M Buy
20,339
+19,069
+1,501% +$955K ﹤0.01% 2057
2017
Q3 		$59K Buy
+1,270
New +$51K ﹤0.01% 2839
2017
Q2 		– Sell
-17,347
Closed -$534K – 2976
2017
Q1 		$534K Sell
17,347
-13,925
-45% -$434K ﹤0.01% 2399
2016
Q4 		$1.05M Buy
+31,272
New +$896K ﹤0.01% 2149

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Russell Investments Group's ENTA Position: Q1 2026 in Review

Russell Investments Group increased its Enanta Pharmaceuticals (ENTA) stake by 534% in Q1 2026, buying an estimated $823K and bringing the position to 72,850 shares worth $915K. The position accounts for ﹤0.01% of the portfolio, ranked #2265.

Russell Investments Group first reported a position in ENTA in Q4 2016 and has held it in 37 quarters since. The position peaked at $9.5M in Q2 2018. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Russell Investments Group held 72,850 shares of Enanta Pharmaceuticals worth $915K as of Q1 2026.
  • Russell Investments Group bought 61,367 Enanta Pharmaceuticals shares in Q1 2026, an estimated $823K.
  • Enanta Pharmaceuticals made up ﹤0.01% of Russell Investments Group's portfolio in Q1 2026, its #2265 holding.
  • Russell Investments Group first reported a position in Enanta Pharmaceuticals in Q4 2016 and has held it in 37 quarters since.
  • Russell Investments Group's Enanta Pharmaceuticals position peaked at $9.5M in Q2 2018.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.